An announcement from Alterity Therapeutics Ltd. ( (AU:ATH) ) is now available.
Alterity Therapeutics Ltd. announced a change in the director’s interest, with Peter Marks acquiring 1,818,182 fully paid ordinary shares through a placement at $0.011 per share. This acquisition reflects an increase in Marks’ stake in the company, potentially signaling confidence in Alterity’s strategic direction and future prospects, which could influence investor sentiment and market perception.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is involved in creating innovative treatments aimed at altering the course of diseases such as Alzheimer’s and Parkinson’s.
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $38.3M
Learn more about ATH stock on TipRanks’ Stock Analysis page.